Recent Advances and Clinical Research in Glaucoma

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (25 February 2024) | Viewed by 1451

Special Issue Editor


E-Mail Website
Guest Editor
Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Interests: glaucoma; fibrosis; epidemiology

Special Issue Information

Dear Colleagues,

Glaucoma is one of the leading causes of permanent vision loss. Despite extensive research efforts, there is still limited knowledge on the etiology of this disease and limited therapeutic options. Our treatment strategy is still mainly focused on lowering the intraocular pressure often without acknowledging the patients’ individual risk factors or potential options for a tailored treatment approach. Patients need personalized treatments. This approach should not only be limited to the clinical decisions ophthalmologists make, but take into account everything from single cell interactions to individual influences.

This Special Issue invites research papers that emphasize this idea and try to develop potential individual approaches to enlighten our understanding of the disease and its treatment.

I would like to especially encourage the submission of interdisciplinary works that might help ophthalmologists to obtain other views of this severe disease.

Prof. Dr. Jan Lübke
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glaucoma
  • risk factors
  • individual treatment
  • disease management
  • tailored medicine

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 1817 KiB  
Article
Complement System Proteins in the Human Aqueous Humor and Their Association with Primary Open-Angle Glaucoma
by Ayushi Vashishtha, Sharon W. Maina, Jeremy Altman, Garrett Jones, Tae Jin Lee, Kathryn E. Bollinger, Lane Ulrich, Marc Töteberg-Harms, Amy J. Estes, Wenbo Zhi, Shruti Sharma and Ashok Sharma
J. Pers. Med. 2023, 13(9), 1400; https://doi.org/10.3390/jpm13091400 - 19 Sep 2023
Cited by 2 | Viewed by 1243
Abstract
This study discovers the complement protein profile in the aqueous humor (AH) of human subjects and investigates its association with primary open-angle glaucoma (POAG) pathogenesis. Among the 32 complement proteins identified, 22 were highly abundant and detected in more than 50% of AH [...] Read more.
This study discovers the complement protein profile in the aqueous humor (AH) of human subjects and investigates its association with primary open-angle glaucoma (POAG) pathogenesis. Among the 32 complement proteins identified, 22 were highly abundant and detected in more than 50% of AH samples. The most predominant active complement proteins in the AH are C3, C4B, C4A, CFB, CFD, and C9. Additionally, the most prevalent complement regulators and receptors include CLU, SERPING1, F2, CFH, CFI, and VTN. Significant alterations in complement proteins were observed in individuals with POAG compared to those with cataracts. Specifically, complement protein F2 was upregulated, while C8G, C6, and CFH were downregulated in POAG samples. Stratification of the samples by race and sex revealed distinct alterations of complement proteins in patients with POAG. In the African American cohort, five complement proteins (C4A, C4B, F2, C7, and C3) were upregulated in POAG compared to cataract patients. In the Caucasian cohort, eight complement proteins (C3, SERPING1, CFI, CLU, CFHR1, C8G, C6, and CFH) were downregulated in the POAG samples compared to the cataract samples. Within the male cohort, three complement proteins (CLU, C6, and CFH) were downregulated in POAG patients compared to those with cataracts. Whereas, within the female cohort, two complement proteins (C4B and F2) were upregulated and one (C8G) downregulated in the POAG samples when compared to cataracts. Discerning these changes in the AH complement protein profile will assist in the development of tailored therapies to modulate the complement system for managing ocular disorders. These insights may also lead to novel biomarkers for diagnosing and monitoring disease progression. Full article
(This article belongs to the Special Issue Recent Advances and Clinical Research in Glaucoma)
Show Figures

Figure 1

Back to TopTop